SanBio Co (JP:4592) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
SanBio Co., Ltd. announced that its development product SB623, aimed at treating chronic motor paralysis due to traumatic brain injury, has shown sustained improvements in motor function and daily activities for up to 48 weeks in a clinical trial. The results of the STEMTRA trial, which demonstrated statistically significant improvements with the medium-dose group, have been published in the journal Neurology. Moreover, the treatment was well tolerated with no new safety concerns.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.
